Vilazodone: Clinical Trials

9 trials of Vilazodone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed. 9 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 39Completed 9

Follow Vilazodone: new trials by email Literature Review of Vilazodone trials Research Report on Vilazodone

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
Vilazodone - Major Depressive Disorder
Phase 3CompletedForest Laboratories3302015-05-022019-09-11
Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)
Vilazodone, Placebo, Fluoxetine - Major Depressive Disorder
Phase 3CompletedForest Laboratories4732015-02-282019-10-01
Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
Placebo, Vilazodone - Major Depressive Disorder
Phase 3CompletedForest Laboratories5292013-07-112019-12-24
Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder
Placebo, Vilazodone - Generalized Anxiety Disorder
Phase 3CompletedForest Laboratories4152013-04-302019-12-18
Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
Vilazodone - Major Depressive Disorder (MDD)
Phase 3CompletedDuke University702012-12-012015-04-16
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Placebo, Vilazodone - Generalized Anxiety Disorder
Phase 3CompletedForest Laboratories6802012-06-302019-12-18
Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)
vilazodone, placebo - Major Depressive Disorder
Phase 3CompletedForest Laboratories4812008-03-012010-10-27
A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)
vilazodone - Major Depressive Disorder
Phase 3CompletedForest Laboratories6162007-12-312017-09-25
Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response
vilazodone - Depressive Disorder, Major
Phase 3CompletedGenaissance Pharmaceuticals4102006-02-012008-02-21

Conditions studied

Depressive Disorder, Major (7)  ·  Generalized Anxiety Disorder (2)

Sponsors

Forest Laboratories (7)  ·  Duke University (1)  ·  Genaissance Pharmaceuticals (1)

Countries

United States (9)  ·  Canada (2)

Top investigators

Carol R Reed, MD (2)  ·  Emily McCusker, PhD (2)  ·  Giovanna Forero, MA (2)  ·  Ashwin A Patkar, MD (1)  ·  Carol Reed, M.D. (1)  ·  Chandran Prakash (1)

Results publications

PMID 22106941, PMID 23216998, PMID 24127687, PMID 24940525, PMID 27486544, PMID 29608461, PMID 19284933, PMID 21527122, PMID 21869687, PMID 25891440, PMID 26693034, PMID 27232052, PMID 29633166